A Novel Herbal Medicine for Dyslipidemia: Assessments in Experimental Models
Table 3
Effect of GANMO on lipid levels in cholesterol-induced dyslipidemia after 4 weeks of treatment.
Groups/treatment on 4th week
n
TG ( ± SD)
TC ( ± SD)
HDL-C ( ± SD)
LDL-C ( ± SD)
Control group
10
0.52 ± 0.10
2.06 ± 0.14
0.92 ± 0.25
0.90 ± 0.24
Model group
10
0.83 ± 0.09
3.55 ± 0.57
1.38 ± 0.38
1.79 ± 0.59
Atorvastatin (10 mg/kg)
10
0.75 ± 0.25
2.93 ± 0.53Δ
1.72 ± 0.20Δ
0.87 ± 0.27ΔΔΔ
GANMO (15.1 g/kg)
10
0.81 ± 0.16
2.82 ± 0.55ΔΔ
1.25 ± 0.19
1.20 ± 0.46Δ
GANMO (45.3 g/kg)
10
0.91 ± 0.19
3.01 ± 0.39Δ
1.45 ± 0.46
1.15 ± 0.38ΔΔ
Note: statistical analysis was done with t test and ANOVA test, and was considered to be statistically significant; : and compared with control group; Δ, ΔΔ, ΔΔΔ: ,, and compared with the model group.